The aggregation and deposition of tau is a hallmark of a class of neurodegenerative diseases 24 called tauopathies. Despite intensive study, cellular and molecular factors that trigger tau 25 aggregation are not well understood. Here we provide evidence for two mechanisms relevant to 26 the initiation of tau aggregation in the presence of cytoplasmic polyphosphates (polyP): changes 27 in the conformational ensemble of monomer tau and noncovalent cross-linking of multiple tau 28 monomers. We identified conformational changes throughout full-length tau, most notably 29 diminishment of long-range interactions between the termini coupled with compaction of the 30 microtubule binding and proline rich regions. We found that while the proline rich and 31 microtubule binding regions both contain polyP binding sites, the proline rich region is a 32 requisite for compaction of the microtubule binding region upon binding. Additionally, both the 33 magnitude of the conformational change and the aggregation of tau are dependent on the chain 34 length of the polyP polymer. Longer polyP chains are more effective at intermolecular, 35 noncovalent cross-linking of tau. These observations provide an understanding of the initial steps 36 of tau aggregation through interaction with a physiologically relevant aggregation inducer.
Abstract 23
The aggregation and deposition of tau is a hallmark of a class of neurodegenerative diseases 24 called tauopathies. Despite intensive study, cellular and molecular factors that trigger tau 25 aggregation are not well understood. Here we provide evidence for two mechanisms relevant to 26 the initiation of tau aggregation in the presence of cytoplasmic polyphosphates (polyP): changes 27 in the conformational ensemble of monomer tau and noncovalent cross-linking of multiple tau 28 monomers. We identified conformational changes throughout full-length tau, most notably 29 diminishment of long-range interactions between the termini coupled with compaction of the 30 microtubule binding and proline rich regions. We found that while the proline rich and 31 microtubule binding regions both contain polyP binding sites, the proline rich region is a 32 requisite for compaction of the microtubule binding region upon binding. Additionally, both the 33 magnitude of the conformational change and the aggregation of tau are dependent on the chain 34
Introduction 54
Neurodegenerative tauopathies are a class of heterogeneous dementias and movement 55 disorders characterized by abnormal accumulation of the microtubule-associated protein tau in 56 insoluble fibrillar aggregates (1). Aggregation transforms soluble, unstructured tau monomers 57 into highly insoluble, β-sheet rich paired helical filaments and neurofibrillary tangles. While the 58 increase of these insoluble aggregates and the progression of symptoms of neurodegeneration are 59 linked, the triggers and mechanisms by which aggregation occurs in the brain are not well 60
characterized. 61
Normally, tau binds to and stabilizes microtubules and plays an important role in the 62 organization of the cytoskeleton of neuronal cells (2). Monomer tau is intrinsically disordered 63 and remains largely disordered even upon binding to microtubules (3, 4) . In vitro, tau is highly 64 soluble and aggregates slowly; polyanionic molecules, such as the extracellular matrix 65 glycosaminoglycan heparin, arachidonic acid or lipid vesicles are commonly used to enhance the 66 rate of aggregation (5-7). We recently demonstrated a similar activity for linear chains of anionic 67 phosphates (i.e. polyphosphate, polyP), which dramatically enhanced the aggregation rates of 68 several amyloidogenic proteins, including tau (8). PolyPs are present at micromolar 69 concentrations in the cytosol of mammalian neurons (9, 10) where they have the potential to 70 interact with tau under normal physiological conditions. 71 Tau aggregation is generally described as nucleation-dependent, with the nucleating 72 species thought to be an "aggregation-prone" monomer (11). Recent evidence in support of this 73 model comes from a study which identified monomer tau derived from heparin-induced 74 aggregates as capable of seeding tau aggregation both in vitro and in cultured cells (12) . A 75 molecular description of the conformational change in monomer tau that predisposes it towards 76 aggregation is of critical importance to developing a complete picture of the molecular 77 determinants of aggregation. However, structural characterization of monomer tau is challenging 78 due to its dynamic, disordered nature. Nuclear magnetic resonance (NMR), which is capable of 79 generating amino acid specific structural information(13), requires high protein concentrations 80 that favor rapid aggregation in the presence of molecular inducers. Work from our lab has 81 established that single molecule Förster resonance energy transfer (FRET) is a powerful 82 approach to characterize conformations of aggregation-prone proteins (14, 15) . 83
In this study, we used single molecule FRET and fluorescence correlation spectroscopy 84 (FCS) to investigate polyP binding to tau. We identified that both the microtubule binding region 85 (MTBR) and the proline rich region (PRR) (Fig. 1 ) contain binding sites for polyP. Moreover, 86
we found that longer polyP polymers were more effective at accelerating tau aggregation than 87 shorter ones. Based on our results, we propose that polyP can serve both as an intramolecular 
93
The longest isoform of tau, 2N4R, is shown. Regions of interest indicated are the N-terminal domain, 94 the proline rich region (PRR), the microtubule binding region (MTBR) and the C-terminal domain.
95
The residues mutated to cysteine for labeling span these regions of interest and are indicated in the 96 schematic. Alternative splicing of N1, N2 and R2 (marked with dashed lines) result in the six isoforms 97 of tau found in human adults.
Materials and Methods 99
Protein purification and labeling 100 Tau constructs were purified based on previously published protocols (15, 16) . Briefly, 101 all variants were expressed with a cleavable N-terminal His-tag. After elution from a nickel 102 column with 400mM mM imidazole, the imidazole concentration was reduced through several 103 buffer exchange cycles using Amicon concentrators (Millipore) and the protein was incubated 104 with tobacco etch virus (TEV) protease at 4 °C overnight. After a second nickel column to 105 remove the enzyme and the cleaved tag, the protein was further purified by size-exclusion 106 chromatography on a HiLoad 16/600 Superdex 200 Column (GE Life Sciences). 107
For site-specific labeling with fluorophores, QuickChange mutagenesis was used to 108 change both native cysteines to serines and to introduce new cysteines at desired locations. For 109 single molecule FRET measurements, cysteines were chosen to span domains of interest as 110 described in the manuscript. For FCS measurements, the protein was labeled with a single 111 cysteine introduced near either the N-or C-terminus. For labeling, freshly purified tau was first 112 reduced with 1 mM DTT for 10 minutes and buffer exchanged into a labeling buffer (20 mM 113 Tris pH 7.4, 50 mM NaCl, and 6 M guanidine HCl) using Amicon concentrators (Millipore) 114 (17). For labeling with donor and acceptor fluorophores for single molecule FRET, protein was 115 incubated stirring at room temperature for an hour with donor fluorophore Alexa Fluor 488 116 maleimide (Invitrogen) at a 2:1 protein:dye ratio. The acceptor fluorophore, Alexa Fluor 594 117 maleimide (Invitrogen) was then added in 5-fold molar excess and incubated stirring overnight at 118 4°C. For single labeling for FCS, Alexa Fluor 488 maleimide was added in 5-fold molar excess 119 to protein and incubated overnight stirring at 4 °C. Labeled protein was buffer exchanged into 20 120 mM Tris (pH 7.4) and 50 mM NaCl and unreacted dye was removed by passing the solution over 121 a HiTrap Desalting Column (GE Life Sciences). 122
123

Aggregation Assays 124
Fibril formation of tau fragments was monitored using Thioflavin T fluorescence. 25 µM 125 tau and 10 µM Thioflavin T were incubated in 40 mM potassium phosphate, 50 mM KCl pH 7.5 126 at 37 °C with 1 mM of different chain length of polyP (polyP kindly provided by T. Shiba 127 (Regenetiss, Japan)) or 18 µM heparin from porcine intestinal mucosa (molecular weight 17-20 128 kDa; Sigma-Aldrich). The polyP concentration is in monomer phosphate units and the heparin 129 concentration was chosen to match the amount of negative charge of the 1 mM polyP. 130
Approximate equivalent charge concentrations of heparin were calculated assuming 1.5 to 2 131 charges and an average molecular weight of 665 g/mol per disaccharide (18 (as defined by the criteria above) were observed for hour-long measurements of 20 µM polyP. 156
The photon traces were analyzed using MATLAB (Mathworks) based lab-written 157 software. For each event, the energy transfer efficiency (ET eff ) value was calculated from: 158
where ! and ! are the fluorescence intensities collected in the acceptor and donor channels, 160 respectively. β accounts for fluorescence from the donor fluorophore on the acceptor channel, 161 and is measured each day varying between 0.7 and 0.85 for both the home-built and commercial 162 systems. γ accounts for differences in detection efficiency and quantum yield for acceptor and 163 donor fluorophores (19) and is measured every few months; γ values used on the lab-built system 164 were 1.36, 1.20 and 1.00 (changes in γ occurred after major realignments or other adjustments to 165 the instrument) and were 1.20 and 1.08 on the commercial Picoquant system (value changed 166 after reinstalling the laser). These individual ET eff values were compiled into histograms and fit 167 by multi-peak Gaussian functions to determine properties of the distributions. We compared 168 ET eff histograms calculated with a correction for the background signal (Eq. 2) (14) with those 169 calculated without one (Eq. 1) 170
Fitting of the histograms yielded equivalent mean ET eff values (Fig. S1) . MHz, were adjusted to be ~30 µW before entering the microscope. Fluorescence emission was 183 collected through the objective and passed through a 100 µm pinhole. Photons were separated by 184 an HQ585LP dichroic in combination with ET525/50M and HQ600LP filters and collected on 185 photodiodes. ET eff and stoichiometry factors were calculated using SymphoTime 64 software 186 and the resultant histograms were fit using Gaussian distributions as described above. Both the 187 lab-built and Microtime 200 instruments were calibrated using 10 base pair, 14 base pair and 18 188 base pair dsDNA standards. 189
The saturating concentration of polyP was determined by a titration of polyP 300 probing 190 the N-terminal domain (tau C17-C149 ) and the PRR and MTBR (tau C149-C372 ) ( averaged to obtain statistical variations and then fit to a diffusion equation using a single-204 component fit using lab-written scripts in MATLAB (The Mathworks). 205
Some measurements were carried out on the MicroTime 200 instrument and analyzed using the 207 SymphoTime 64 software. 208
Noncovalent cross-linking measurements were carried out using 25 µM unlabeled 4R, 20 209 nM single labeled 4R and 1 mM polyP or 18 µM heparin at 20 °C. Triplicate measurements with 210 25 curves of 10 seconds were recorded immediately after mixing. The cross-linking FCS 211 measurements were carried out at a lower temperature (20 °C) than the aggregation assays (37 212 °C). Aggregation occurs more slowly at lower temperatures such that it is unlikely that large 213 fibrillar aggregates are formed during the duration of the FCS measurements. 214
215
Competition Assays 216
Tubulin was purified from bovine brain tissue using repeated cycles of polymerization 217 and depolymerization in the presence of a high-molarity PIPES buffer (21). Before use, tubulin 218 was clarified by centrifugation at 100,000g and buffer-exchanged into phosphate buffer. 219
Competitive binding of tubulin and polyP to tau was measured by FCS. ~20 nM P2-4R was 220 incubated with 5 µM tubulin for 5 minutes at 20 °C. PolyP 300 was added to the tau-tubulin 221 sample at concentrations ranging from 1 µM to 100 µM, and incubated for 5 minutes before Functionally, tau can be divided into four major domains (Fig. 1) . The function of the N-236 terminal domain is the least well-understood, although it has been proposed to regulate binding 237 to microtubules (22) and Methods for details and correction factors). Higher ET eff values correspond to shorter 257 distances between the donor and acceptor dyes, whereas lower ET eff values reflect longer 258 distances. ET eff values were plotted as histograms and fit with a sum of Gaussian distributions to 259 determine the peak ET eff positions (Fig. 2) . As an intrinsically disordered protein, tau populates 260 an ensemble of conformations. For simplicity and convenience in comparing FRET 261 measurements of different tau constructs or under different experimental conditions, we use the 262 mean ET eff obtained from fitting to reflect the average of tau's conformational ensemble for a 263 given measurement. Measurements were made in the absence (Fig. 2, dashed lines) or presence 264 of polyP 300 (average of 300 phosphate units per polymer) (Fig. 2, solid lines) ; polyP 265 concentrations are given in monomer P i units. 266
267
PolyP disrupts long-range intramolecular interactions in tau 268
In solution, tau is a compact protein despite its length and intrinsic disorder, with the N-269 and C-termini in relatively close proximity to the MTBR (15). 2N3R is 31 residues shorter than 270 2N4R due to the absence of R2; thus, differences in the measured ET eff between the two isoforms 271 for constructs that span this region, i.e., tau C149-C372 (MTBR and PRR) and tau C17-C433 (entire 272 protein) are expected and observed ( Fig. 2; Table S1 ). Interestingly, the construct probing the C-273 terminal domain tau C372-C433 , which is identical in both isoforms, shows a lower ET eff for 2N3R 274 than 2N4R, reflecting a more extended conformational ensemble for 2N3R. 
286
Statistical analysis of repeat measurements is given in Table S1 .
288
The addition of polyP 300 resulted in an increase in the average end-to-end distance of tau 289 as reflected by the decrease in ET eff for both 2N4R (Fig. 2a) and 2N3R (Fig. 2b ) tau C17-C433 290 (Table S1 ). These results suggested that polyP disrupts some of the long-range electrostatic 291 interactions that are responsible for tau's relatively compact conformational ensemble in 292 solution. We also noted a similar polyP-mediated shift to lower ET eff values, i.e., larger 293 distances, for both isoforms when the N-and C-terminal domains were probed independently, 294 using tau C17-C149 or tau C372-C433 , respectively (Fig. 2c, d and Fig. 2g, h ; Table S1 ). In contrast, 295 tau C149-C372, which probes the region encompassing the PRR and MTBR, showed a relatively 296 large shift towards higher ET eff values for both isoforms, reflecting significant compaction of this 297 region (Fig 2e, f; Table S1 ). Increasing the ionic strength of the buffer solution to 500 mM KCl 298 eliminated the observed changes in the ET eff histograms for 2N4R tau C17-C149 or tau C149-C372 (Fig.  299   S3) , supporting the idea that electrostatic interactions are important for polyP binding to tau. 300
These results are similar to our previous results on tau-heparin interactions (15) Table S2 .
318
PolyP binds to the PRR and MTBR 319
The MTBR carries an effective net charge of +10.2 and +7.1 at pH 7.4 in the 2N4R and 320 2N3R isoforms, respectively, while the PRR has a net charge of +13.8. Thus, our expectationwas that the negatively charged polyP binds to these domains and that changes in the 322 conformational ensembles in other regions of the protein may result from screening of the 323 positive MTBR and PRR by the anionic polyP. For example, binding of polyP to the MTBR or 324 PRR may disrupt the long-range interactions with the negatively charged N-terminal domain, 325 thereby altering its conformational ensemble even if polyP does not bind directly to the N-326 terminal domain. To identify the regions of tau involved in polyP binding, we made six tau 327 fragments ( Fig. 3 ): 4R and 3R, which correspond to the MTBR (residues 244-372) of 2N4R and 328 2N3R, respectively; P1P2, which is the entire PRR (residues 148-245); P2-4R and P2-3R, which 329 contain 4R and 3R as well the second half of the PRR (residues 198-372); and NT, which 330 corresponds to the N-terminal domain (residues 1-152). The fragments and full-length tau 331 constructs were labeled with a single fluorophore and fluorescence correlation spectroscopy 332 (FCS) was used to measure their diffusion times in the absence or presence of polyP 14 or 333 polyP 300 . A change in mass or hydrodynamic radius of tau upon binding polyP is expected to 334 result in a change in tau's diffusion time ( Fig. S4 ; details in Materials and Methods). All 335 constructs except for NT (which showed no change) exhibited an increase in diffusion time 336 ranging from 11 to 24% in the presence of polyP 300 relative to the diffusion time of the construct 337 in the absence of polyP 300 , indicative of polyP binding ( Fig. 3 ; Table S2 ). The two fragments 338 lacking R2 in their MTBRs (i.e., P2-3R and 3R), however, showed reproducibly less of an 339 increase in diffusion time upon binding polyP than their 4R counterparts (i.e., P2-4R and 4R), 340
suggesting that presence of R2 enhances the interactions with polyP (Fig. 3) . Moreover, addition 341 of the shorter polyP 14 caused similar increases in the diffusion times although of smaller 342 magnitudes than observed for polyP 300 (Fig. 3) . Based on these results, we concluded that polyP 343 binds to both the PRR and MTBR. In addition, the observed lack of polyP binding to the NT 344 indicated that the large conformational changes that we observed when we probed the N-terminal 345 domain in the context of the full-length protein, tau C17-C149 (Fig. 2c, d) is not due to direct binding 346 of polyP to this domain but caused by an overall reconfiguration of tau's conformational 347 ensemble upon binding of polyP to the PRR and MTBR. 348
To understand the relationship between polyP's binding to the PRR and MTBR and the 349 conformational changes that we observed by smFRET (Fig. 2) , we conducted smFRET 350 measurements focusing on either the MTBR (Fig. 4a-c for 4R ; Fig. 4d-f for 3R ) or the PRR (Fig.  351 4g-i) in the context of the full-length constructs or select fragments. In the absence of polyP, the 352 fragments generally showed higher mean ET eff values than the full-length proteins, indicating 353 that the flanking regions of the protein impact the conformational ensembles sampled by the 354 various domains even in solution (Fig. 4 , dashed lines; Table S3 ). Full-length tau C244-C372 355 constructs exhibited a large shift to higher ET eff upon binding polyP, reflecting a polyP-induced 356 compaction of the MTBR (Fig. 4a, d ; Table S3 ). We observed similar results for P2-4R C244-C372 357 and P2-3R C244-C372 constructs ( Fig. 4b, e ; Table S3 ), although the magnitudes of the shifts were 358 not as great as those seen in the full-length proteins. Interestingly, polyP did not cause any 359 significant shifts in the ET eff values in either of the isolated MTBR fragments, 4R C244-C372 or 360 3R C244-C372 ( Fig. 4c, f; Fig. S5 and Table S3 ) despite clear evidence of binding to this region as 361 measured by FCS (Fig. 3) . However, comparison of the ET eff histograms revealed that binding of 362 polyP to both the full-length tau or the shorter P2-4R C244-C372 and P2-3R C244-C372 constructs shifts 363 their peak positions close to those of the isolated MTBR fragments, 4R C244-C372 or 3R C244-C372 . 364
These results suggest that the MTBR fragments in isolation populate a compact monomer 365 conformational ensemble that is only achieved in the longer tau constructs through binding of 366 polyP. Since isolated MTBR fragments aggregate more readily than full-length tau (31) 
378
Statistical analysis of repeat measurements is given in Table S3.   379   380 SmFRET measurements of the other tau fragments were consistent with FCS measurements that 381 showed binding to P1P2 but not NT. PolyP binding to the isolated PRR, P1P2 C149-C244 caused a 382 shift to higher ET eff ( Fig. 4i; Table S3 ), although not as great as seen in full-length tau C149-C244 383 ( Fig. 4g, h ; Table S3 ). No shift in ET eff was detected in the isolated N-terminal fragment, NT C17-384 C149 ( Fig. S5 ; Table S3 ). 385
386
PolyP enhances tau aggregation through intermolecular cross-linking 387
In vivo, polyP exists as a broad range of polymer lengths (10) and our prior work with 388 polyP revealed that longer chains are generally more effective at accelerating aggregation of 389 amyloidogenic proteins than shorter ones (8). To examine whether a relationship exists between 390 polyP chain length, changes to the conformational ensemble of the monomer protein and 391 aggregation propensity, we conducted smFRET measurements on select full-length 2N4R 392 constructs, tau C17-C149 (Fig. 5a ) and tau C149-C372 (Fig. 5b) in the presence of saturating 393 concentrations of polyP 14 , polyP 60 , polyP 130 or polyP 300 (Table S4 ). In the presence of polyP 14 , 394 tau C149-C372 underwent a very small increase in ET eff while the tau C17-C149 conformation appeared 395 to be unchanged ( Fig. 5 ; Table S4 ). This was despite the fact that polyP 14 binds to both the full-396 length protein as well as to the isolated fragments (Fig. 3) . All other polyP chain lengths caused 397 large shifts in the mean ET eff for both tau C17-C149 and tau C149-C372 to the previously observed lower 398 and higher values, respectively ( Fig. 5; Table S4 ). This suggests that for longer polyP polymers, 399 a single chain may be able to bind to multiple binding sites on tau to allow for intra-molecular 400 scaffolding resulting in a change in its conformational ensemble. When the chain is not long 401 enough (i.e. polyP 14 ) this effect is not observed. Table S4.   419   420 Ensemble aggregation experiments were carried out for tau fragments in the presence of 421 various chain lengths of polyP. Aggregation was monitored by an increase in Thioflavin T 422 fluorescence and quantified by the T 1/2 , the time to reach half the signal plateau ( Fig. 6; Fig. S6  423 and Table S5 ; details in Materials and Methods). While an inverse relationship between the T 1/2 424 and the length of polyP was observed for both 3R and 4R, all polyP chain lengths were more 425 effective at inducing aggregation than heparin (Fig. 6 ). To illustrate, while the T 1/2 of 4R was 426 over 15 hours in the presence of heparin, it was less than 6 hours in the presence of polyP 14 and 427 less than 10 minutes in the presence of polyP 300 . Consistent with previous findings that the 4R-428 fragment of tau is generally more aggregation-prone than the 3R-fragment (33) (e.g., T 1/2 of 15 429 hours versus 60 hours in the presence of heparin), the influence of all polyP chains wasaccordingly less pronounced for the 3R-fragment. Moreover, while polyP was effective in 431 accelerating the aggregation of the two 4R constructs (R4 and P2-R4), it was less effective at 432 inducing aggregation of 3R as compared to P2-3R ( Fig. 6 ; Table S5 ). These data, along with the 433 binding data shown in Fig. 3 , support the importance of polyP binding to both R2 and the PRR 434 for effective acceleration of aggregation; constructs which contain either P2 (i.e., P2-3R), R2 435 (i.e, 4R) or both (i.e., P2-4R) aggregate significantly faster in the presence of polyP than 3R, 436 which lacks both binding sites. 437
Our smFRET and aggregation data support the conclusion that binding of polyP to 438 multiple intramolecular sites increases the efficacy of polyP in initiating tau aggregation. 439
Moreover, our finding that longer polyP chains are more effective in stimulating tau aggregation 440 suggest that longer polyP chains are able to interact with several tau monomers, thereby serving 441 as an intermolecular scaffold to non-covalently cross-link tau monomers. FCS and smFRET 442 measurements are typically carried out at pM to nM protein concentrations, which strongly 443 disfavor intermolecular protein interactions. To directly test whether polyP is able to non-444 covalently cross-link tau monomers, we conducted FCS measurements at concentrations of 4R 445 and polyP that are comparable to our ensemble aggregation experiments. The addition of 25 µM 446 unlabeled 4R to 20 nM labeled 4R did not result in a change in its diffusion time, indicating that 447 tau-tau interactions are not favored at the increased protein concentration in the absence of polyP 448 ( Fig. S7a and b) . With the addition of 1 mM polyP 300 , however, extremely heterogeneous 449 autocorrelation curves were recorded, suggesting the formation of large oligomeric assemblies or 450 aggregates ( Fig. 6f) (7) . In contrast, the addition of 1 mM polyP 14 resulted in only a few aberrant 451 autocorrelation curves, reflecting fewer large species (Fig. 6g) . These results suggest that longer 452 polyP chains enhance intermolecular tau-tau interactions, which might play an important role in 453 the acceleration of tau aggregation. 454 455 Table S5 .
462
PolyP is more effective at accelerating tau aggregation than heparin 463
Heparin is the most commonly used inducer of tau aggregation in vitro (5). To investigate 464 whether heparin and polyP trigger similar changes in the conformational ensemble of tau, wecompared their effects on tau in smFRET experiments. We measured two 2N4R constructs, 466 tau C17-C149 and tau C149-C372 , using concentrations of heparin (MW ~17,000g) of 130 nM and 1.75 467 µM, which have the same equivalent charge as ~5 µM and 80 µM polyP, respectively. At these 468 concentrations, heparin induced shifts in the mean ET eff in the same direction as polyP, although 469 the magnitude of the shift was reproducibly smaller ( Fig. 7; Table S6 ). Moreover, heparin does 470 not appear to be as effective scaffold for binding multiple tau monomers (Fig. S7c) , as polyP 300 471 and heparin-induced aggregation of tau displayed a significantly slower kinetics than measured 472 in the presence of polyP ( Fig. 6b and 6c) . Together, these data demonstrate that compared to 473 heparin, polyP is significantly more effective at i) populating a more compact, aggregation-prone 474 conformational ensemble of tau, ii) cross-linking multiple tau monomers, and consequently iii) 475 inducing tau aggregation. 
503
PolyP competes with tubulin for tau binding 504
In vitro, polyP binds to tau and is very effective in accelerating its aggregation. In 505 neurons, there are many other biomolecules that can compete with polyP for binding to tau. The 506 most relevant of these is tubulin, tau's primary cellular binding partner. We therefore decided to 507 investigate whether polyP is a competitive binding partner of tau that is capable of affecting tau's 508 ability to interact with tubulin in vitro. For these experiments, we used the P2-4R fragment, 509 which undergoes conformational changes (Fig. 4) and aggregates readily (Fig. 6 ) upon binding 510 polyP and is known to interact with both soluble tubulin (34) and microtubules (35) in vitro. As a 511
reporter for tubulin binding, we measured the diffusion time of fluorescently labeled P2-4R in 512 the absence and presence of 5 µM tubulin by FCS ( Fig. 8; Fig. S8 ). Consistent with our previous 513 work, binding of P2-4R to tubulin resulted in an increase in the diffusion time from ~0.66 ms to 514 ~0.93 ms (36). Upon titration with polyP 300 , we observed a polyP concentration-dependent 515 decrease in the diffusion time, reflecting competitive displacement of tubulin from P2-4R by 516 polyP (Fig. 8 ). In the presence of 100 µM polyP 300 , the diffusion time of P2-4R was comparable 517 to that measured for P2-4R with saturating concentrations of polyP in the absence of tubulin 518 (Fig. 3) , suggesting that polyP had effectively replaced all of the bound tubulin. 519 520 Discussion 521
Our results identified three aspects of the interaction between tau and polyP relevant to its 522 mechanism of enhancing tau aggregation: (1) binding of polyP to tau's MTBR and PRR regions, 523 which changes the conformational ensemble of monomer tau by causing compaction of those 524 domains; (2) screening of electrostatic interactions between tau domains and disruption of long 525 range interactions between tau's termini and MTBR; and (3) facilitating intermolecular 526 association of tau monomers (Fig. 9) . 527
SmFRET measurements of full-length tau constructs most clearly illustrated that polyP 528 binding causes both local (compaction of the PRR and MTBR) and long-range (loss of 529 interaction between the termini and central region) changes in tau's conformational ensembles 530 (Fig. 2) . We found that polyP binds to both PRR and MTBR regions, yet compaction of the 531 MTBR domain is only observed in the presence of the PRR (compare Fig. 4b and c) . We reason 532 that the observed changes in the conformational ensemble result from the noncovalent 533 intramolecular cross-linking of binding sites in the PRR and MTBR by a single polyP chain (Fig.  534   9 ). Further evidence in support of this idea came from the use of polyP of different chain lengths. 535
Even at saturating concentrations, we found that polyP 14 , which is too short to span between 536 binding sites in the PRR and MTBR (37), causes only a slight shift in the mean ET eff of full-537 length tau (Fig. 5) while longer chain lengths (polyP 60 , polyP 130 and polyP 300 ) cause much largershifts. Interestingly, the shift caused by polyP 60 is to a higher mean ET eff value than that of 539 polyP 130 and polyP 300 for tau C149-C372 (Fig. 5b) . The shorter end-to-end distance of polyP 60 may 540 not be able to span between binding sites without imposing a more compact conformational 541 ensemble on tau. This effect is likely only seen for the tau C149-C372 construct (Fig. 5b) but not 542 tau C17-C149 (Fig. 5a ) because only the probes for the former encompass the PRR and MTBR 543 binding sites. 544
We consider that both charge screening and intermolecular cross-linking are likely 545 relevant to the general capability of polyP to accelerate tau aggregation. The tau fragments are 546 highly positively charged, disfavoring intermolecular interactions in solution. Indeed, FCS 547 measurements with high concentrations of unlabeled monomer 4R show no evidence of tau 548 assembly (Fig. S7) . Binding of negatively charged polyP decreases the electrostatic repulsion 549 between monomers so that intermolecular interactions become more favorable and binding of 550 polyP to tau is effectively blocked by increasing the buffer ionic strength (Fig. S3) . While all 551 polyP chain lengths are capable of accelerating aggregation through this mechanism (Fig. 6b) , 552 longer polyPs are more effective because they are also capable of facilitating binding to multiple 553 tau monomers, effectively increasing their local concentration (Fig. 6f, g and Fig. 9 ). The fact 554 that polyP most effectively accelerates the aggregation of tau fragments that contain both P2, in 555 the PRR, and R2, in the MTBR suggests that the presence of additional binding sites may 556 facilitate intermolecular scaffolding by polyP. 557 
564
One challenge faced by in vitro aggregation studies is translating their results to a more 565 physiological context. For example, while disease models generally describe alterations to tau 566 (such as mutations found in tauopathies) as enhancing the aggregation propensity of tau, the 567 effects in vitro are usually fairly moderate (1, 38). Natively, tau is associated with either 568 microtubules (35, 39) or soluble tubulin (40), although this interaction is likely to be highly 569 dynamic (25, 26) . We find that polyP is able to displace tubulin from tau (Fig. 8) at 570 concentrations much lower than the reported cytosolic concentrations of polyP (41). The cellular 571 cytoplasm is much more complex than the tertiary mixture explored here and thus whether polyP 572 could compete for binding to tau under physiological conditions remains to be tested. However, 573 our measurements strongly suggest that polyP is capable of binding tau in the presence of tubulinor microtubules. Moreover, under pathological conditions where tau binding to microtubules is 575 compromised by mutation or hyperphosphorylation (42), the cytoplasmic pool of tau available to 576 interact with polyP is increased. Future studies will investigate whether tubulin-dissociated, 577 polyP-bound monomer might be putative target for therapeutics (reviewed in (43). Our results 578 here provide insight into the conformational features of this monomer and may eventually aid in 579 the design of therapeutics to combat tauopathies. 
